During the corresponding time, Staar Surgical Co recorded a revenue increase by 111.04 % year on year, sequentially revenue grew by 0.01 %. While revenue at the Staar Surgical Co's corporate clients
STAAR Surgical, a major developer, manufacturer and marketer of the Implantable Collamer Lenses (ICL), has announced a strategic breakthrough in its U.S. Highway 93 go-to-market program. The firm has reached an agreement with IQ Laser Vision, a premier EVO ICL practice in North America, to enhance its services in refractive eye surgery. Based in Lake Forest, California and publically traded on NASDAQ (STAA), STAAR Surgical has carved a niche for itself in the field of surgical vision correction. Its well-known product line, the EVO family of ICLs is used in the treatment of myopia, astigmatism, and presbyopia.This new partnership brings together two critical players in the eye-care industry with a shared foc...
STAAR Surgical, a prominent player in the field of vision correction, recently marked a significant milestone in their business journey. The company announced that it has successfully sold over three million units of its revolutionary Implantable Collamer Lenses (ICLs) worldwide. This noteworthy accomplishment is a testament to the trust and confidence placed in STAAR Surgical s products by both medical professionals and patients seeking advanced solutions for myopia, astigmatism, and presbyopia.Partnerships Driving Success:With an unwavering commitment to delivering cutting-edge technology in vision correction, STAAR Surgical acknowledges the invaluable support of surgeons and clinicians who collaborate clo...
The demand for innovative vision correction solutions has been on the rise in recent years, as more individuals seek alternatives to glasses and contact lenses. In response to this growing trend, STAAR Surgical Company (NASDAQ: STAA), a renowned developer and manufacturer of Implantable Collamer Lenses (ICL), has entered into a strategic agreement with SharpeVision, a premier ophthalmology group with clinics in Seattle, Chicago, and Austin. This groundbreaking partnership aims to revolutionize the way individuals with myopia, astigmatism, and presbyopia gain visual freedom, potentially marking a significant shift in the eyecare landscape.The Promise of the EVO ICL:STAAR Surgical s EVO family of Implantable C...
Sources:
Staar Surgical Co’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Staar Surgical Co’s corporate clients.
For your research, we’ve provided 9 tables on Staar Surgical Co corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
106.68 %